NCT06621329View on ClinicalTrials.gov

Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

October 31, 2026

Conditions
SAH (Subarachnoid Hemorrhage)Headache
Interventions
COMBINATION_PRODUCT

Transnasal sphenopalatine ganglion block

Transnasal sphenopalatine ganglion blocks will be performed using the Tx360 device. Medications used during the procedure include 0.75% bupivacaine with or without 1 mg of preservative free dexamethasone.

Trial Locations (1)

95817

RECRUITING

UC Davis Medical Center, Sacramento

All Listed Sponsors
collaborator

Agnes Marshall Walker Foundation

UNKNOWN

lead

University of California, Davis

OTHER